Assessment of the effectiveness of early treatment in SARS-CoV-2 infection
© 2021 MEDPRESS..
Treatment of SARS-CoV-2 infection has been undertaken in all medical centers in the world. Based on the experience gained, in some of them it was possible to effectively control the course of the Corona virus infection depending on the stage of infection.
AIM: The aim of the study was to assess the effectiveness of early treatment depending on the stage of SARS-CoV-2 infection and the severity of symptoms, mainly in the respiratory system.
MATERIALS AND METHODS: Outpatient treatment included 104 patients infected with SARS-CoV-2, in whom infection was confirmed according to the adopted criteria. The first group of patients were infected with SARS-CoV-2 with mild symptoms, the time of probable infection was 3- 5 days ago. They were given arechin (Arechin, Adamed) 2 times 1 tablet (250 mg) for 6 days, azithromycin (Sumamed, Teva) 1 time a day 1 tablet (500 mg) for 6 days. After confirmation of persistence of cracks at the base of the lungs, treatment was continued by administering methylprednisolone (Metypred, Orion) orally at a dose of 0.2 mg/kg in reducing doses every 5 days and ciclesonide (Alvesco, Takeda Pharma) by inhalation 2 x 160 μg each. The second group consisted of people infected with SARS-CoV-2, who had not been treated, but were taking only antipyretic drugs and reported 7-10 days after the onset of infection. After revealing "ground-glass opacity" changes in chest CT, it was recommended to take levofloxacin (Levoxa, Actavis Polska) twice a day, 1 tablet (500 mg) for 3 days, and then once a day for the next 5-7 days, of methylprednisolone orally in a dose of 0.3 mg/kg in weight in decreasing doses every 5 days, according to changes found in imaging tests, and inhalation of ciclesonide 2 x 160 μg. Patients after COVID-19, hospitalized with respiratory disorders and changes in imaging tests, were the third group. They were treated according to the extent of the changes in chest CT and comorbidities, using methylprednisolone orally at a dose of 0.5 mg/kg in doses reducing every 5-10 days, depending on the rate of symptom relief and regression of changes in the tests. imaging and inhaled ciclesonide 2 x 320 μg. In each case, the treatment was individually selected according to the severity of the course of the disease.
RESULTS: In all patients, a significant improvement in general condition was achieved in the form of relief of dyspnea, cough and weakness, which correlated with a significant remission of the initial changes in the pulmonary parenchyma in the form of a "ground-glass opacity". In the first group, after the treatment (from 3-5 days after infection), only 17.6% of patients in the CT examination of the chest showed the presence of peripheral lesions of the "ground-glass opacity" type with an extent of 1-25%, and in 35.3% of patients "cotton foci". In the second group (treated from 7-10 days after infection), 18.7% of patients revealed the presence of "ground-glass opacity" lesions, which occupy more than 50% of the pulmonary parenchyma, and in 31.2% more than 25% of patients. After treatment, COVID-19 symptoms resolved, and chest CT showed a significant reduction in lesions - in 21.8% of patients <25% and in 25% of patients <10%. In the third group of COVID-19 patients after hospitalization, symptoms of the "groundglass opacity" type dominated, including in as many as 37.5% they affected more than 50% of the pulmonary parenchyma, and over 25% in 42.8% of the treated. After treatment, a significant reduction in the symptoms of the disease and an improvement in the CT image of the chest were achieved - in 50% of patients lung involvement <5% and in 28.6% with lesions <10%.
CONCLUSIONS: The effectiveness of azithromycin, arechin, methylprednisolone and ciclesonide in controlling inflammation caused by SARSCoV- 2 infection has been confirmed in treated patients with symptoms of COVID-19 on an outpatient basis. The use of the assessed drugs should take into account the time of onset of SARS-CoV-2 infection and the severity of the disease course, including comorbidities. The presented analysis of the effectiveness of early treatment in patients infected with SARS-CoV-2 requires further clinical trials.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego - 49(2021), 294 vom: 16. Dez., Seite 394-400 |
| Sprache: |
Polnisch |
|---|
| Weiterer Titel: |
Ocena skuteczności wczesnego podejmowania leczenia w zakażeniu SARS-CoV-2 |
|---|
| Beteiligte Personen: |
Płusa, Tadeusz [VerfasserIn] |
|---|
| Themen: |
Arechin |
|---|
| Anmerkungen: |
Date Completed 21.12.2021 Date Revised 03.04.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM334552443 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334552443 | ||
| 003 | DE-627 | ||
| 005 | 20231225223939.0 | ||
| 007 | tu | ||
| 008 | 231225s2021 xx ||||| 00| ||pol c | ||
| 028 | 5 | 2 | |a pubmed24n1115.xml |
| 035 | |a (DE-627)NLM334552443 | ||
| 035 | |a (NLM)34919080 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a pol | ||
| 100 | 1 | |a Płusa, Tadeusz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessment of the effectiveness of early treatment in SARS-CoV-2 infection |
| 246 | 3 | 3 | |a Ocena skuteczności wczesnego podejmowania leczenia w zakażeniu SARS-CoV-2 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 21.12.2021 | ||
| 500 | |a Date Revised 03.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 MEDPRESS. | ||
| 520 | |a Treatment of SARS-CoV-2 infection has been undertaken in all medical centers in the world. Based on the experience gained, in some of them it was possible to effectively control the course of the Corona virus infection depending on the stage of infection | ||
| 520 | |a AIM: The aim of the study was to assess the effectiveness of early treatment depending on the stage of SARS-CoV-2 infection and the severity of symptoms, mainly in the respiratory system | ||
| 520 | |a MATERIALS AND METHODS: Outpatient treatment included 104 patients infected with SARS-CoV-2, in whom infection was confirmed according to the adopted criteria. The first group of patients were infected with SARS-CoV-2 with mild symptoms, the time of probable infection was 3- 5 days ago. They were given arechin (Arechin, Adamed) 2 times 1 tablet (250 mg) for 6 days, azithromycin (Sumamed, Teva) 1 time a day 1 tablet (500 mg) for 6 days. After confirmation of persistence of cracks at the base of the lungs, treatment was continued by administering methylprednisolone (Metypred, Orion) orally at a dose of 0.2 mg/kg in reducing doses every 5 days and ciclesonide (Alvesco, Takeda Pharma) by inhalation 2 x 160 μg each. The second group consisted of people infected with SARS-CoV-2, who had not been treated, but were taking only antipyretic drugs and reported 7-10 days after the onset of infection. After revealing "ground-glass opacity" changes in chest CT, it was recommended to take levofloxacin (Levoxa, Actavis Polska) twice a day, 1 tablet (500 mg) for 3 days, and then once a day for the next 5-7 days, of methylprednisolone orally in a dose of 0.3 mg/kg in weight in decreasing doses every 5 days, according to changes found in imaging tests, and inhalation of ciclesonide 2 x 160 μg. Patients after COVID-19, hospitalized with respiratory disorders and changes in imaging tests, were the third group. They were treated according to the extent of the changes in chest CT and comorbidities, using methylprednisolone orally at a dose of 0.5 mg/kg in doses reducing every 5-10 days, depending on the rate of symptom relief and regression of changes in the tests. imaging and inhaled ciclesonide 2 x 320 μg. In each case, the treatment was individually selected according to the severity of the course of the disease | ||
| 520 | |a RESULTS: In all patients, a significant improvement in general condition was achieved in the form of relief of dyspnea, cough and weakness, which correlated with a significant remission of the initial changes in the pulmonary parenchyma in the form of a "ground-glass opacity". In the first group, after the treatment (from 3-5 days after infection), only 17.6% of patients in the CT examination of the chest showed the presence of peripheral lesions of the "ground-glass opacity" type with an extent of 1-25%, and in 35.3% of patients "cotton foci". In the second group (treated from 7-10 days after infection), 18.7% of patients revealed the presence of "ground-glass opacity" lesions, which occupy more than 50% of the pulmonary parenchyma, and in 31.2% more than 25% of patients. After treatment, COVID-19 symptoms resolved, and chest CT showed a significant reduction in lesions - in 21.8% of patients <25% and in 25% of patients <10%. In the third group of COVID-19 patients after hospitalization, symptoms of the "groundglass opacity" type dominated, including in as many as 37.5% they affected more than 50% of the pulmonary parenchyma, and over 25% in 42.8% of the treated. After treatment, a significant reduction in the symptoms of the disease and an improvement in the CT image of the chest were achieved - in 50% of patients lung involvement <5% and in 28.6% with lesions <10% | ||
| 520 | |a CONCLUSIONS: The effectiveness of azithromycin, arechin, methylprednisolone and ciclesonide in controlling inflammation caused by SARSCoV- 2 infection has been confirmed in treated patients with symptoms of COVID-19 on an outpatient basis. The use of the assessed drugs should take into account the time of onset of SARS-CoV-2 infection and the severity of the disease course, including comorbidities. The presented analysis of the effectiveness of early treatment in patients infected with SARS-CoV-2 requires further clinical trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a arechin | |
| 650 | 4 | |a azithromycin | |
| 650 | 4 | |a ciclesonide | |
| 650 | 4 | |a methylprednisolone | |
| 650 | 4 | |a stage of infection | |
| 650 | 4 | |a treatment | |
| 773 | 0 | 8 | |i Enthalten in |t Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego |d 1997 |g 49(2021), 294 vom: 16. Dez., Seite 394-400 |w (DE-627)NLM090955315 |x 1426-9686 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2021 |g number:294 |g day:16 |g month:12 |g pages:394-400 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2021 |e 294 |b 16 |c 12 |h 394-400 | ||